Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CDH2
REST API REST API
Homo sapiens
CDH2 is differentially expressed in 283 experiments: 189 organism parts: lung, brain, ... (187 more);, 251 disease states: normal, chronic myelogenous leukemia, ... (249 more);, 100 cell types 514 cell lines 26 compound treatments and 78 other conditions.
Synonyms NCAD, CD325, CDHN
Orthologs CADH2_BOVIN (Bos taurus)   CADH2_CHICK (Gallus gallus)   cdh2 (Danio rerio)   Cdh2 (Mus musculus)   Cdh2 (Rattus norvegicus)   cdh2 (Xenopus laevis)   Q9GKK9_CANFA (Canis familiaris)   CadN2 (Drosophila melanogaster)   (Compare orthologs)
Gene Ontology Term cell migration, plasma membrane, adherens junction, calcium-dependent cell-cell adhesion, adherens junction organization, protein binding, synapse assembly, regulation of axonogenesis, cell-cell adherens junction, cell-cell adhesion, beta-catenin binding, heterophilic cell-cell adhesion, cell-cell junction, protein complex, membrane, homophilic cell adhesion, cell-cell junction organization, membrane fraction, regulation of protein localization, regulation of Rho protein signal transduction, cell adhesion, protein kinase binding, muscle cell differentiation, lamellipodium, synapse, integral to membrane, calcium ion binding, RPTP-like protein binding, striated muscle cell differentiation, synapse part, gamma-catenin binding, alpha-catenin binding, catenin complex, fascia adherens, regulation of myelination, protein phosphatase binding, positive regulation of MAPKKK cascade, negative regulation of canonical Wnt receptor signaling pathway, positive regulation of muscle cell differentiation, blood vessel morphogenesis, cell junction assembly
InterPro Term Pleckstrin_homology, Cadherin, Cadherin_cytoplasmic-dom, Cadherin_pro, Desmocollin
UniProt Accession C9J126, C9J8J8, A8MWK3, C9JMH2, P19022
Search EB-eye ENSG00000170558
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-2549, E-GEOD-7540, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-19397, E-GEOD-4717, ... (42 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823
K562
2
E-MTAB-37, E-GEOD-24147
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MDA-MB-231
2
E-TABM-420, E-MTAB-62
SW480
2
E-MEXP-1014, E-MTAB-37
U251
2
E-GEOD-20089, E-MTAB-62
508 more value(s).


Cell type

studied in E-MEXP-2426, E-GEOD-3920, E-MEXP-120, E-GEOD-20677, E-GEOD-2822, ... (49 experiments)

Factor Value U/D Experiments
endothelial cell
1
3
E-GEOD-3920, E-GEOD-96, E-GEOD-3998, E-GEOD-19240
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
2
E-TABM-145, E-TABM-130
testis - germ cell
2
E-AFMX-5, E-TABM-145
embryonic stem cell
1
2
E-MEXP-930, E-MEXP-2426, E-GEOD-2248
CD4+ T cell
1
2
E-MTAB-24, E-MTAB-25, E-AFMX-5
94 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-MTAB-62, E-GEOD-5370, ... (52 experiments)

Factor Value U/D Experiments
chronic myelogenous leukemia
4
E-GEOD-5550, E-MTAB-62, E-GEOD-96, E-MTAB-37
glioblastoma
4
E-MTAB-62, E-MTAB-37, E-GEOD-6014, E-GEOD-4290
prostate carcinoma
4
E-MTAB-62, E-MEXP-2034, E-GEOD-7307, E-GEOD-96
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
lymphoma
2
E-MTAB-37, E-MTAB-62
colon carcinoma
2
E-MTAB-37, E-MTAB-62
245 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-5741, E-TABM-782, E-GEOD-5824, E-MEXP-1958, ... (17 experiments)

Factor Value U/D Experiments
sapphyrin PCI-2054
1
E-GEOD-6400
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
TGF-Beta1
1
E-MEXP-2645
Cxcl12
1
E-GEOD-7307
LDL
1
1
E-GEOD-5741
estradiol
1
E-GEOD-20081
20 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-19246, E-GEOD-2034, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (8 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease free interval dfi in months
studied in E-GEOD-22541

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138, E-GEOD-3013 ... (5 experiments)

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (8 experiments)

Genotype
studied in E-TABM-763, E-GEOD-22056, E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-10315, E-GEOD-837, E-MEXP-1273, E-GEOD-20505, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-TABM-276, E-GEOD-20194, E-GEOD-16716, ... (6 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-GEOD-3606, E-GEOD-16363, ... (29 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-9723, E-MEXP-561, E-GEOD-980, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-4600

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-1343

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-2115, E-GEOD-1676, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70

Sex
studied in E-GEOD-19743, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-4922 ... (5 experiments)

Tumor size
studied in E-GEOD-8167

Processing time: 0.384 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM